Background: potentially inappropriate prescribing (PIP) is associated with adverse health effects in older patients. PIP comprises prescription of potentially inappropriate medications (PIMs) and potential prescribing omissions (PPOs). Objective: to estimate the prevalence of PIMs and PPOs among older patients in primary care. Design: retrospective longitudinal study. Setting: routinely collected data of 182,000 patients of 49 general practitioners (GPs) gathered in the GPs' database of the Academic Medical Center of Amsterdam, the Netherlands. Subjects: in each studied year, all patients who were aged 65 years and older at 1st January. Methods: the prevalence of patients with at least one PIM and patients with at least one PPO was measured in 8 subsequent years by application of the Screening Tool of Older Persons potentially inappropriate Prescriptions (STOPP)/Screening Tool to Alert doctors to Right Treatment (START) criteria. Multivariate logistic regression was used to evaluate trends in the prevalence of PIMs and PPOs over the years. Results: on average, 4,537 patients were included per investigated year. The mean prevalence of ≥1 PIM was 34.7% (range 34.0-35.6%) and of ≥1 PPO 84.8% (range 77.4-90.6%). Examples were the prescription of salicylates without a proper indication and the absence of a therapeutically indicated vitamin D prescription. The prevalence of ≥1 PPOs showed a statistically significant decrease over the investigated years (OR 0.87, P < 0.001), whereas the prevalence of PIMs did not change significantly. Conclusions: this study underscores the need for more attention to medication prescribing to older patients. The prevalence of PIP among older patients in primary care is substantial and the prevalence of PIMs did not decrease over time.
Introduction
Potentially inappropriate prescribing (PIP) is associated with adverse drug reactions (ADRs), hospitalisation, increased healthcare utilisation and death in older patients [1] [2] [3] [4] [5] . Inappropriate prescribing comprises the prescription of drugs when the risk of adverse effects outweighs the potential benefits, as well as the omission of drug prescribing in situations where medication is actually indicated [6] .
In order to identify PIP to older patients and improve prescribing quality, several screening tools were developed [7] , of which the Beers' list was the first in 1991 in the United
States, containing medication that should be avoided or adapted in older patients, i.e. potentially inappropriate medication (PIM) [8] . The Beers' list has two important limitations, i.e. the focus on the American drug market and the restriction to PIMs. The European Screening Tool of Older Persons' potentially inappropriate Prescriptions (STOPP) and the Screening Tool to Alert doctors to Right Treatment (START) [9] were developed based on commonly encountered PIMs, and listed according to physiological systems. The original version of the STOPP/START criteria was developed in Ireland and translated into a Dutch version in 2012 [10] .
Previous studies in primary care in western Europe that applied the STOPP/START criteria revealed an estimated prevalence of PIMs measured as proportion of all included patients between 21% and 56% [1, [11] [12] [13] [14] [15] [16] [17] [18] , and of potential prescribing omissions (PPOs) between 23% and 46% [14, 15, 17] . However, these studies have several limitations. First, all but two studies were performed cross-sectionally or evaluated a single year. As has been shown, a seasonal variation exists in medical care expenditure, which includes the use of medication and diseases [19] . The results of cross-sectional studies could therefore be biased due to seasonal or epidemical variations in medication use or occurrence of diseases [20, 21] . Second, individual STOPP/START criteria may be interpreted differently, because of a lack of unambiguous definitions, e.g. a 'high risk for osteoporosis' or 'long-term use of opiates'. Most of the studies were inconclusive on the specification of the STOPP/START criteria, which might hamper comparison. Finally, more than half of the studies that focused on PIMs applied less than 80% of the STOPP criteria due to incomplete medical records; [1, 12, 13, [15] [16] [17] the studies that did apply all STOPP criteria included less than 900 patients [11, 14, 18] .
Recently, the Dutch version of the STOPP/START criteria has been specified in the standardised terms of ICD9 (International Classification of Diseases), ICPC (International Classification of Primary Care) and ATC (Anatomical Therapeutic and Chemical) codes, which facilitates computerised application in research and clinical practice [22] . The aim of the current study is to estimate the prevalence of PIMs and PPOs in primary care in the Netherlands among older people, by application of the above-mentioned specification of the STOPP/START criteria.
Methods Study setting and population
A retrospective study of routinely collected data was conducted in 8 subsequent years (from 2007 to and including 2014). This study was performed using the general practitioners' (GP) research database of the Academic Medical Center (AMC) in the Netherlands. The database contains anonymized records of a cohort of more than 182,000 patients of 49 GPs in the southeast of Amsterdam. Data include the date of birth, gender, current diagnoses and medical history as coded according to the ICPC, summaries of consultations, results of diagnostic tests and drug prescriptions. The drug prescription records include ATC codes, dosage, and start and stop prescription dates.
Inclusion criteria in each investigated year were: age of 65 years and older, ≥1 drug prescription and/or ≥1 visits to the GP and/or a registered laboratory test in the investigated year or the first half of the following year. In addition, at least 1 year of data had to be available prior to the investigated year. Patients were followed until death or leaving the participating GP centres.
Variables
PIMs and PPOs were defined based on a recently published translation of the Dutch version of the STOPP/START criteria, with specified ATC and ICPC codes based on a multidisciplinary expert consensus procedure [22] . In the present study, the first version of the STOPP/START criteria was used, since the second version was published after the years of interest, i.e. in 2014 [23] . Patients were identified as having a PIM if the start date of the PIP was within the investigated year. In order to apply the START criteria, a period was selected in which prescribing should have taken place after the occurrence of a prescribing indication (intended start period). A PPO was registered if the indicated prescription was absent, or was provided after the intended start period. The number of continuously prescribed drugs per patient was calculated, i.e. medication for which patients received at least three prescriptions in the investigated year.
Data extraction
In total, 61 out of 62 STOPP and 25 out of 26 START criteria were applied to the database records. The computer scripts used to apply these criteria were checked by a clinical pharmacologist and a medical computer scientist. Two criteria could not be applied; one due to insufficient data and one due to programming restrictions. Some data had to be calculated using additional information or formulas from previously published studies, for example end dates of episodes belonging to temporary diseases and the glomerular filtration rate [24, 25] . All computer scripts were validated manually by checking a sample of the identified cases, and with a simulation model containing 10 fictive patients.
Data analysis
The outcome of this study comprised the prevalence of at least one PIM and the prevalence of at least one PPO as proportion of all eligible patients. Additionally, the prevalence of PIMs and PPOs per individual STOPP/START criterion was measured as proportion of all included patients. All outcome measures were calculated per investigated year and as weighted mean, in which the weight of each year was based on the number of included patients. Multivariate logistic regression was used to examine whether age and gender were associated with PIMs and PPOs and to examine the statistical significance of observed trends in both raw and adjusted prevalence of PIMs and PPOs over the investigated years. Other variables which might influence PIMs and PPOs, such as social demographic characteristics, were not added to the multivariate logistic regression, since they were not available in the database.
Data extraction and statistical analyses were performed using the R statistical environment (version 3.2.2 for Windows, R Foundation for Statistical Computing, Vienna, Austria) using the packages readr and dplyr.
Ethical statement
The data used in this study were part of an anonymized database of routinely collected data and therefore approval of an Ethics Review Board was not necessary.
Results

Patient characteristics
The overall mean number of patients aged 65 years and older per year was 4,537 (range 4,134 to 5,217; Table 1 ). Over the investigated years, the mean age ranged between 74.1 and 76.1 years.
Mean prevalence of PIMs and PPOs
On average, 34.7% of all patients received ≥1 PIM within a year (95% CI: 34.2-35.2; Figure 1 ). The mean proportion of patients with ≥1 PPO was 84.8% (95% CI: 84.4-85.2). Logistic regression showed that female gender (OR 1.30, P < 0.001), age (OR 1.01 per year, P < 0.001) and the number of continuously prescribed drugs (OR 1.27, P < 0.001) were significantly associated with having PIMs. Female gender (OR 3.70, P < 0.001) and age (OR 1.12 per year, P < 0.001) were significantly associated with having PPOs. There was no significant change in the prevalence of ≥1 PIM over the investigated years. Both raw and age-adjusted and gender-adjusted analyses of the prevalence of ≥1 PPO showed a statistically significant (OR 0.87, P < 0.001) decrease over the investigated years.
Number of PIMs and PPOs per patient
On average, per year, 23.4% of all patients received one PIM (range 22.4-24.3%). Of all patients, 3.5% (range 3.1-4.1%) received three or more PIMs. The proportion of patients with one, two and three or more PIMs did not change significantly over time. One PPO was present in 45.1% (range 43.0-47.0%) and three or more in 15.9% (range 10.1-21.2%) of patients. After adjustment for gender and age, the percentage of patients with one PPO increased significantly over time (OR 1.01 per year, P < 0.01), whereas the percentage of patients with two (OR 0.97 per year, P < 0.001) and three or more PPOs (OR 0.89 per year, P < 0.001) decreased significantly over the investigated years.
Prevalence of PIMs and PPOs per individual STOPP/ START criterion
On average, 10.4% of all patients received a prescription for salicylates while they had no vascular indication (Table 2) . Moreover, 2.5% of all patients received dipyramidole as monotherapy although concomitant prescription of acetylsalicylic acid was indicated. Of patients with a history of falling or a tendency to fall, 20.2% received a prescription for benzodiazepines, 12.9% a prescription for opiates and 7.5% a prescription for antipsychotic agents. Of patients with heart failure, 11.8% received ≥1 prescription for nonsteroidal anti-inflammatory drugs (NSAIDs) in 1 year, which is contra-indicated. The same accounted for 8.2% of patients with chronic renal failure.
Regarding PPOs, 16.4% of all patients received a prescription for opiates without concomitant prescription of laxatives, 
Discussion
The present study showed that more than one-third (34.7%) of patients aged 65 years and older were prescribed medications that were potentially inappropriate. Moreover, potentially beneficial medications were absent in more than 8 out of 10 patients (84.8%). Whereas the percentage of patients with one or more PPOs showed a statistically significant decrease over the investigated years, the proportion of patients with at least one PIM did not change significantly over time.
The mean prevalence of PIMs fits halfway the range between 21% and 56% reported elsewhere [1, [11] [12] [13] [14] [15] [16] [17] [18] . However, the results of the current study might not be comparable to other studies due to different study designs, different inclusion criteria or regional differences.
The mean prevalence of PPOs was considerably higher than that reported in previous studies (i.e. 84.8% compared to values ranging from 23% to 46%) [14, 15, 17] . The percentage of women aged ≥50 years and men aged ≥70 years lacking a prescription of vitamin D was much higher in the present study (75%) than in other studies (less than 20%). In the Netherlands, GPs regularly advice patients to buy vitamin D over the counter (OTC), since there is no reimbursement for this vitamin if prescribed by a physician, and a recipe is more expensive than OTC medication. As a result, OTC prescriptions in the database are absent. The situation in the present study of OTC use of vitamin D might have led to overestimation of PPOs. When the prevalence of PPOs was measured without the application of the criterion concerning vitamin D, the prescription of at least one potentially beneficial medicine was omitted in almost half (47.2%) of patients.
It should be noted that studies based on routinely collected healthcare databases have certain limitations. OTC medication is commonly not registered, and medication prescribed in secondary care is not always registered. Moreover, the ICPC coding system is not flawless, e.g. not every diagnose has its own ICPC code. In addition, routinely collected healthcare data are prone to unidentified errors. Since PIMs and PPOs were not clinically evaluated in the current study, some identified PIMs/PPOs might actually be well considered instead of inappropriate, for reasons such as limited life expectancy, unclear benefit-risk balances or a patient's refusal to use the medication [26] . Furthermore, in the current study, dates of recovery of episodes of temporary diseases were calculated, because these were missing in the vast majority of cases. Leaving out the dates of recovery would have led to an extensive overestimation of PIMs and PPOs. The exclusion of patients without a drug prescription, consultation or lab result between 1st January of the investigated year, and 1st June of the year thereafter could have led to an overestimation of PIP, since these individuals are likely to be relatively healthy. Nevertheless, this exclusion was necessary in order to rule out a larger group of patients that are mistakenly present in the GP system (e.g. deceased patients and patients that moved out of the GP practice). Besides the limitations due to the study design, it must be noted that the current study was conducted in six GP practices in the southeast of Amsterdam and that the results may not be generalisable to different regions in the Netherlands and other countries.
In spite of these limitations, this is the first study that applied more than 95% of the STOPP/START criteria to records of more than 4,500 older patients in eight subsequent years. All previous studies that did apply all criteria included less than 900 patients. By means of application of the criteria to our extensive study population a more reliable estimation of the prevalence could be established. Moreover, this is the first study evaluating eight subsequent years. Other strengths are the availability of complete patient files and the clear specification of the applied STOPP/START criteria. Studies using pharmacy claim databases could have been more accurate on medication use, but were unable to apply all STOPP/START criteria, since no diagnoses are registered in such databases [12, 13, 15] .
The present study draws attention to the fact that PIP is highly prevalent among older patients in primary care, although the STOPP/START criteria exist since 2008, and are incorporated in the Dutch multidisciplinary guideline on polypharmacy in older patients that was published in 2012. Apparently, insufficient actions have been taken to enhance appropriate prescribing, since the percentage of patients having PIMs did not decrease significantly over 8 years. Furthermore, although the prevalence of PPOs did decrease over time, it remained substantial, implying that older people are not prescribed medication that can be considered beneficial or even necessary for their health. It has been shown that underprescription is widespread in primary care as well as secondary care [26] . Several reasons for inappropriate underprescription were mentioned, such as multimorbidity, ageism and lack of scientific evidence. Although the STOPP/START criteria concern potentially inappropriate prescribing, and therefore one might question the clinical relevance of each criterion, research shows that PIMs are responsible for a substantial part of the ADRs contributory to hospital admissions and that a considerable part of these ADRs are preventable [1] [2] [3] . Most common ADRs caused by PIMs and PPOs defined based on the STOPP/START criteria and contributing to hospital admissions include: falls during benzodiazepine therapy, falls while receiving opiates and constipation while receiving opiates [2] . The present study showed that the proportion of patients having these PIMs and PPOs is substantial (i.e. 0.47%, 0.30% and 16.38%, respectively), and that the prevalence of these PIMs/PPOs did not decrease over time. For these reasons, medication reviews applying the STOPP/START criteria should be implemented in daily practice. Although Dutch GPs confirm the importance of the criteria, they do not have time to routinely optimise drug prescribing to older patients [27] . An electronic method to identify PIP, as used in this study, could enhance the application of the criteria. Besides that, the comprehensiveness of the criteria are considered a barrier to implementation [27] . It would be preferable if the STOPP/START criteria would provide a hierarchy of PIP, from most clinically urgent and relevant to clinically useful, non-urgent advice. Then GPs would have guidance in the order in which medication should be stopped or started. In addition, pharmacists could assist the GPs in the medication reviews. Although little research has been performed concerning the costeffectiveness and efficiency of application of the STOPP/ START criteria in primary care, application of the STOPP/START criteria in geriatric care facilities led to a cost reduction of 29 dollars per patient per month [28] . In summary, these findings demonstrate the benefits of and the need for application of the STOPP/START criteria.
In conclusion, this study underlines the need for more attention to the optimisation of medication prescribing to older patients in general practice.
Key points
• The prevalence of potentially inappropriate prescribing to older patients in primary care is substantial.
• The prevalence of potentially inappropriate medications did not decrease over a period of 8 years.
• More attention is needed to optimise medication prescribing to older patients.
